European Commission publishes first joint clinical assessment under EU HTA regulation
The European Commission released the first joint clinical assessment (JCA) report on 9 June for the orphan medicine tovorafenib (Ojemda®), developed by Ipsen, used to treat paediatric low-grade glioma (a type of brain tumour), after being endorsed by all member states. This marks an important milestone for European cooperation on health technology assessments (HTA) under the HTA regulation which came into force January 2025. The JCA was conducted with the Irish National Centre for Pharmacoeconomics (NCPE) as the assessor and the German Institute for Quality and Efficiency in Health Care (IQWiG) as the co-assessor.
How to read this article
Thank you for visiting Regulatory Rapporteur, you have now used up your content views.
To continue reading:
If you are a TOPRA member, or have already registered for limited free access, log in now (Option 1 below).
Not yet a member? You can either join TOPRA (Option 2 below), or register to view limited content for free (Option 3 below).
The Organisation for Professionals in Regulatory Affairs
- Contact us
- Copyright © 2015-2026 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved